Bristol-Myers Squibb Company (BMY) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

BMY Stock Forecast


Bristol-Myers Squibb Company stock forecast is as follows: an average price target of $65.50 (represents a 12.48% upside from BMY’s last price of $58.23) and a rating consensus of 'Hold', based on 20 wall street analysts offering a 1-year stock forecast.

BMY Price Target


The average price target for Bristol-Myers Squibb Company (BMY) is $65.50 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $85.00 to $41.00. This represents a potential 12.48% upside from BMY's last price of $58.23.

BMY Analyst Ratings


Hold

According to 20 Wall Street analysts, Bristol-Myers Squibb Company's rating consensus is 'Hold'. The analyst rating breakdown for BMY stock is 0 'Strong Buy' (0.00%), 7 'Buy' (35.00%), 12 'Hold' (60.00%), 1 'Sell' (5.00%), and 0 'Strong Sell' (0.00%).

Bristol-Myers Squibb Company Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Evan SeigermanBMO Capital--8.49%4.76%
Nov 01, 2024Evan David SeigermanBMO Capital--4.93%-2.11%
Sep 23, 2024Evan David SeigermanBMO Capital---3.15%-17.57%
Jul 29, 2024Chris ShibutaniGoldman Sachs--12.77%-2.11%
Jul 29, 2024Carter GouldBarclays---18.73%-29.59%
Jul 12, 2024Trung HuynhUBS--5.70%-26.15%
May 16, 2024Steve ScalaCowen & Co.--51.89%15.06%
Jan 30, 2024James ShinDeutsche Bank--10.29%-5.55%
Nov 27, 2023Evan SeigermanBMO Capital--20.58%3.04%
Oct 12, 2023David RisingerLeerink Partners--17.34%13.34%
Row per page
Go to

The latest Bristol-Myers Squibb Company stock forecast, released on Nov 12, 2024 by Evan Seigerman from BMO Capital, set a price target of $61.00, which represents a 8.49% increase from the stock price at the time of the forecast ($56.23), and a 4.76% increase from BMY last price ($58.23).

Bristol-Myers Squibb Company Price Target by Period


1M3M12M
# Anlaysts239
Avg Price Target$59.00$55.33$54.33
Last Closing Price$58.23$58.23$58.23
Upside/Downside1.32%-4.98%-6.70%

In the current month, the average price target of Bristol-Myers Squibb Company stock is $59.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 1.32% increase as opposed to Bristol-Myers Squibb Company's last price of $58.23. This month's average price target is up 6.63% compared to last quarter, and up 8.60% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024DaiwaOutperformUpgrade
Nov 04, 2024Leerink PartnersMarket PerformMarket PerformHold
Oct 17, 2024BernsteinMarket PerformInitialise
Oct 09, 2024UBSNeutralNeutralHold
Oct 07, 2024JefferiesMarket PerformMarket PerformHold
Oct 07, 2024Deutsche BankUnderperformUnderperformHold
Oct 07, 2024BarclaysUnderweightUnderweightHold
Sep 23, 2024BMO CapitalMarket PerformMarket PerformHold
Sep 16, 2024Goldman SachsBuyBuyHold
Aug 28, 2024JefferiesHoldHoldHold
Row per page
Go to

Bristol-Myers Squibb Company's last stock rating was published by Daiwa on Nov 13, 2024. The company Upgrade its BMY rating from "null" to "Outperform".

Bristol-Myers Squibb Company Financial Forecast


Bristol-Myers Squibb Company Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$10.97B$11.23B$11.34B$11.41B$11.22B$11.89B$11.65B$11.98B$11.62B$11.70B$11.07B$11.07B$10.54B$10.13B$10.78B$7.95B$6.01B
Avg Forecast$11.34B$11.29B$11.43B$11.06B$11.78B$11.62B$11.91B$11.71B$11.53B$11.26B$11.54B$11.48B$11.19B$10.96B$11.77B$11.50B$11.19B$11.14B$11.42B$11.36B$12.04B$11.61B$11.27B$11.13B$10.73B$10.32B$9.99B$10.03B$7.12B$5.90B
High Forecast$11.51B$11.46B$11.60B$11.22B$11.95B$11.79B$12.09B$11.88B$11.79B$11.27B$11.54B$11.50B$11.53B$11.16B$11.94B$11.66B$11.35B$11.14B$11.42B$11.36B$12.04B$11.61B$11.27B$11.13B$10.73B$10.32B$9.99B$10.03B$7.12B$5.90B
Low Forecast$11.18B$11.13B$11.26B$10.90B$11.61B$11.45B$11.74B$11.70B$11.40B$11.26B$11.54B$11.47B$10.78B$10.82B$11.59B$11.33B$11.02B$11.14B$11.42B$11.36B$12.04B$11.61B$11.27B$11.13B$10.73B$10.32B$9.99B$10.03B$7.12B$5.90B
# Analysts11111112149749168912778138891359644
Surprise %-------------1.00%0.95%0.99%1.02%1.01%1.04%1.03%1.00%1.00%1.04%0.99%1.03%1.02%1.01%1.08%1.12%1.02%

Bristol-Myers Squibb Company's average Quarter revenue forecast for Dec 23 based on 9 analysts is $11.19B, with a low forecast of $10.78B, and a high forecast of $11.53B. BMY's average Quarter revenue forecast represents a 2.06% increase compared to the company's last Quarter revenue of $10.97B (Sep 23).

Bristol-Myers Squibb Company EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111112149749168912778138891359644
EBITDA-------------$4.21B$4.16B$5.10B$4.71B$5.30B$5.39B$5.08B$4.76B$5.21B$4.59B$5.54B$-7.41B$5.25B$4.54B$2.53B$1.39B$1.72B
Avg Forecast$3.83B$3.81B$3.85B$3.73B$3.97B$3.92B$4.02B$3.95B$3.89B$3.80B$3.89B$5.03B$3.77B$3.69B$3.97B$4.57B$4.82B$4.22B$4.32B$4.15B$4.56B$4.40B$4.27B$5.79B$4.06B$3.91B$3.78B$2.14B$2.70B$2.23B
High Forecast$3.88B$3.86B$3.91B$3.78B$4.03B$3.98B$4.08B$4.01B$3.98B$3.80B$3.89B$6.03B$3.89B$3.76B$4.03B$5.48B$5.79B$4.22B$4.32B$4.99B$4.56B$4.40B$4.27B$6.94B$4.06B$3.91B$3.78B$2.56B$2.70B$2.23B
Low Forecast$3.77B$3.75B$3.80B$3.68B$3.91B$3.86B$3.96B$3.95B$3.85B$3.80B$3.89B$4.02B$3.64B$3.65B$3.91B$3.66B$3.86B$4.22B$4.32B$3.32B$4.56B$4.40B$4.27B$4.63B$4.06B$3.91B$3.78B$1.71B$2.70B$2.23B
Surprise %-------------1.14%1.05%1.12%0.98%1.26%1.25%1.22%1.04%1.18%1.08%0.96%-1.82%1.34%1.20%1.18%0.52%0.77%

9 analysts predict BMY's average Quarter EBITDA for Dec 23 to be $3.77B, with a high of $3.89B and a low of $3.64B. This is -10.44% lower than Bristol-Myers Squibb Company's previous annual EBITDA (Sep 23) of $4.21B.

Bristol-Myers Squibb Company Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111112149749168912778138891359644
Net Income-------------$1.93B$2.07B$2.26B$2.02B$1.61B$1.42B$1.28B$2.37B$1.55B$1.05B$2.02B$-10.03B$1.87B$-85.00M$-775.00M$-1.06B$1.35B
Avg Forecast$3.52B$4.08B$3.76B$3.26B$3.48B$3.75B$3.87B$3.75B$2.99B$3.03B$3.29B$1.51B$3.16B$3.58B$3.98B$1.37B$2.59B$3.71B$3.59B$1.24B$3.64B$3.89B$3.83B$2.11B$2.87B$3.02B$3.01B$-655.37M$1.79B$2.18B
High Forecast$3.58B$4.15B$3.83B$3.32B$3.55B$3.82B$3.94B$3.95B$3.25B$3.13B$3.29B$1.81B$3.55B$3.79B$4.06B$1.64B$3.10B$3.71B$3.59B$1.49B$3.74B$3.89B$3.83B$2.53B$2.87B$3.02B$3.01B$-524.30M$1.79B$2.18B
Low Forecast$3.45B$4.00B$3.69B$3.20B$3.42B$3.67B$3.79B$3.55B$2.85B$2.94B$3.29B$1.20B$2.86B$3.40B$3.91B$1.10B$2.07B$3.71B$3.59B$995.64M$3.55B$3.89B$3.83B$1.69B$2.87B$3.02B$3.01B$-786.44M$1.79B$2.18B
Surprise %-------------0.54%0.52%1.65%0.78%0.43%0.40%1.03%0.65%0.40%0.28%0.96%-3.49%0.62%-0.03%1.18%-0.59%0.62%

Bristol-Myers Squibb Company's average Quarter net income forecast for Dec 23 is $3.16B, with a range of $2.86B to $3.55B. BMY's average Quarter net income forecast represents a 63.67% increase compared to the company's last Quarter net income of $1.93B (Sep 23).

Bristol-Myers Squibb Company SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111112149749168912778138891359644
SG&A-------------$2.00B$1.93B$1.76B$2.27B$1.93B$1.79B$1.83B$2.35B$1.79B$1.88B$1.67B$2.72B$1.71B$1.63B$1.61B$1.73B$1.05B
Avg Forecast$1.98B$1.97B$2.00B$1.93B$2.06B$2.03B$2.08B$2.05B$2.02B$1.97B$2.02B$2.16B$1.96B$1.92B$2.06B$1.96B$2.55B$1.95B$2.00B$1.78B$2.11B$2.03B$1.97B$1.74B$1.88B$1.80B$1.75B$1.36B$1.24B$1.03B
High Forecast$2.01B$2.00B$2.03B$1.96B$2.09B$2.06B$2.11B$2.08B$2.06B$1.97B$2.02B$2.59B$2.02B$1.95B$2.09B$2.35B$3.06B$1.95B$2.00B$2.14B$2.11B$2.03B$1.97B$2.09B$1.88B$1.80B$1.75B$1.63B$1.24B$1.03B
Low Forecast$1.95B$1.95B$1.97B$1.91B$2.03B$2.00B$2.05B$2.05B$1.99B$1.97B$2.02B$1.73B$1.88B$1.89B$2.03B$1.57B$2.04B$1.95B$2.00B$1.43B$2.11B$2.03B$1.97B$1.39B$1.88B$1.80B$1.75B$1.09B$1.24B$1.03B
Surprise %-------------1.05%0.94%0.90%0.89%0.99%0.89%1.03%1.12%0.88%0.96%0.96%1.45%0.95%0.93%1.18%1.39%1.02%

Bristol-Myers Squibb Company's average Quarter SG&A projection for Dec 23 is $1.96B, based on 9 Wall Street analysts, with a range of $1.88B to $2.02B. The forecast indicates a -2.30% fall compared to BMY last annual SG&A of $2.00B (Sep 23).

Bristol-Myers Squibb Company EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11111112149749168912778138891359644
EPS-------------$0.94$0.99$1.08$0.96$0.75$0.67$0.60$1.10$0.70$0.47$0.90$-4.45$0.83$-0.04$-0.34$-0.55$0.83
Avg Forecast$1.73$2.01$1.85$1.61$1.72$1.84$1.90$1.85$1.47$1.49$1.62$-4.41$1.55$1.76$1.96$1.97$1.73$1.83$1.77$1.91$1.80$1.92$1.89$1.81$1.42$1.49$1.48$1.49$0.88$1.07
High Forecast$1.76$2.05$1.89$1.64$1.75$1.88$1.94$1.94$1.60$1.54$1.62$-4.33$1.75$1.86$2.00$2.01$1.76$1.83$1.77$1.91$1.84$1.92$1.89$1.81$1.42$1.49$1.48$1.49$0.88$1.07
Low Forecast$1.70$1.97$1.82$1.58$1.68$1.81$1.87$1.75$1.40$1.45$1.62$-4.50$1.41$1.67$1.92$1.93$1.69$1.83$1.77$1.91$1.75$1.92$1.89$1.81$1.42$1.49$1.48$1.49$0.88$1.07
Surprise %-------------0.53%0.50%0.55%0.56%0.41%0.38%0.31%0.61%0.36%0.25%0.50%-3.14%0.56%-0.03%-0.23%-0.62%0.77%

According to 9 Wall Street analysts, Bristol-Myers Squibb Company's projected average Quarter EPS for Dec 23 is $1.55, with a low estimate of $1.41 and a high estimate of $1.75. This represents a 65.29% increase compared to BMY previous annual EPS of $0.94 (Sep 23).

Bristol-Myers Squibb Company Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PFEPfizer--78.11%Hold
BIIBBiogen--75.05%Buy
MRKMerck--29.07%Buy
JNJJohnson & Johnson--15.20%Buy
BMYBristol-Myers Squibb Company--12.48%Hold
AMGNAmgen--4.11%Buy
LLYEli Lilly and Company--3.76%Buy
ABBVAbbVie--0.91%Buy
GILDGilead Sciences---8.90%Buy

BMY Forecast FAQ


Is Bristol-Myers Squibb Company a good buy?

No, according to 20 Wall Street analysts, Bristol-Myers Squibb Company (BMY) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 35.00% of BMY's total ratings.

What is BMY's price target?

Bristol-Myers Squibb Company (BMY) average price target is $65.5 with a range of $41 to $85, implying a 12.48% from its last price of $58.23. The data is based on 20 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Bristol-Myers Squibb Company stock go up soon?

According to Wall Street analysts' prediction for BMY stock, the company can go up by 12.48% (from the last price of $58.23 to the average price target of $65.5), up by 45.97% based on the highest stock price target, and down by -29.59% based on the lowest stock price target.

Can Bristol-Myers Squibb Company stock reach $90?

BMY's average twelve months analyst stock price target of $65.5 does not support the claim that Bristol-Myers Squibb Company can reach $90 in the near future.

What is Bristol-Myers Squibb Company's current price target trend?

2 Wall Street analysts forecast a $59 price target for Bristol-Myers Squibb Company (BMY) this month, up 1.32% from its last price of $58.23. Compared to the last 3 and 12 months, the average price target decreased by -4.98% and decreased by -6.70%, respectively.

What are Bristol-Myers Squibb Company's analysts' financial forecasts?

Bristol-Myers Squibb Company's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $47.03B (high $47.72B, low $46.5B), average EBITDA is $15.86B (high $16.09B, low $15.68B), average net income is $14.84B (high $15.25B, low $14.44B), average SG&A $8.22B (high $8.34B, low $8.13B), and average EPS is $7.31 (high $7.51, low $7.11). BMY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $45.12B (high $45.78B, low $44.47B), average EBITDA is $15.22B (high $15.44B, low $15B), average net income is $14.61B (high $14.89B, low $14.34B), average SG&A $7.89B (high $8.01B, low $7.78B), and average EPS is $7.19 (high $7.33, low $7.06).

Did the BMY's actual financial results beat the analysts' financial forecasts?

Based on Bristol-Myers Squibb Company's last annual report (Dec 2023), the company's revenue was $45.01B, which missed the average analysts forecast of $45.41B by -0.89%. Apple's EBITDA was $17.24B, beating the average prediction of $16.01B by 7.71%. The company's net income was $8.02B, missing the average estimation of $12.09B by -33.63%. Apple's SG&A was $7.77B, missing the average forecast of $7.89B by -1.51%. Lastly, the company's EPS was $3.88, missing the average prediction of $7.25 by -46.49%. In terms of the last quarterly report (Sep 2023), Bristol-Myers Squibb Company's revenue was $10.97B, beating the average analysts' forecast of $10.96B by 0.10%. The company's EBITDA was $4.22B, beating the average prediction of $3.69B by 14.07%. Bristol-Myers Squibb Company's net income was $1.93B, missing the average estimation of $3.58B by -46.19%. The company's SG&A was $2B, beating the average forecast of $1.92B by 4.56%. Lastly, the company's EPS was $0.94, missing the average prediction of $1.76 by -46.72%